STAT3 Signalling in Cancer: The IL-6/JAK/STAT3 Axis

How STAT3 Is Switched On

Cytokines such as IL-6 bind receptors that activate JAK kinases. JAKs phosphorylate STAT3, which then dimerises, enters the nucleus and binds DNA. Receptor tyrosine kinases and non-receptor kinases such as SRC can also phosphorylate STAT3.

In normal cells this signalling is transient and tightly switched off by phosphatases and SOCS proteins. In tumours the off-switches are often weakened and IL-6 is abundant in the microenvironment, so STAT3 stays on.

What Persistent STAT3 Does to the Tumour Cell

Active STAT3 drives transcription of proliferation and survival genes, including cyclin D1, MYC, survivin and BCL-XL, and it supports metabolic and angiogenic programmes.

It also promotes an invasive, stem-like state in some cancers, which is associated with treatment resistance.

STAT3 and the Immune Microenvironment

STAT3 signalling in tumour and immune cells dampens the anti-tumour immune response. It reduces production of pro-inflammatory mediators that would recruit cytotoxic cells and supports regulatory and myeloid-derived suppressor populations.

This immunosuppressive role is a major reason there is interest in combining STAT3-axis inhibition with immune-checkpoint blockade.

Why STAT3 Has Been Hard to Drug

STAT3 is a transcription factor without an obvious enzymatic pocket, so direct inhibitors have struggled with potency and selectivity. Most clinical progress has come from targeting upstream nodes: anti-IL-6 and anti-IL-6-receptor antibodies, and JAK inhibitors, several of which are approved for inflammatory disease and myeloproliferative neoplasms.

Antisense oligonucleotides and protein degraders against STAT3 are in earlier development.

Interpretation Notes

Nuclear phospho-STAT3 staining or a STAT3 gene signature is a research readout of pathway activity, not a validated companion diagnostic.

Activating STAT3 mutations are seen in specific conditions such as large granular lymphocytic leukaemia, but in most solid tumours STAT3 activity is driven by upstream signalling rather than by mutation of the gene itself.

Key Takeaways

• ·IL-6 and JAK kinases are the main route to STAT3 activation in cancer.
• ·Persistent STAT3 drives survival genes and suppresses anti-tumour immunity.
• ·Direct STAT3 inhibitors remain difficult; upstream JAK and IL-6 blockade is further along.
• ·STAT3 activity readouts are research tools, not standard predictive tests.